Sarcopenia News - LARVOL Sigma

Sarcopenia	Welcome, Profile Billing Logout

«1 2...57 58 59 60 616263 64 65 66 67...401 402 »

|||||||||| Journal: Analysis of Risk Factors for the Association of Sarcopenia in Patients with Type 2 Diabetes Mellitus. (Pubmed Central) - Apr 2, 2024
Low BMI and lower serum levels of 25 (OH) D and IGF-1 are risk factors of sarcopenia in patients with T2DM. Low BMI, 25(OH)D, IGF-1, and testosterone (for men) all contributed to the prediction of sarcopenia, among which BMI and combined factors were more significant.

|||||||||| Assessment of sarcopenia improves the prediction of post-TIPS mortality in older adult patients with cirrhosis (Space 3) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2310;
Due to its significant impact on survival, the evaluation of sarcopenia improves the selection of older adults with cirrhosis candidate to TIPS. The new predictive model for post-TIPS liver- related mortality deserves validation.

|||||||||| Sarcopenia, frailty and growth hormone-insulin like growth factor axis among decompensated and alcohol-associated hepatitis patients (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2291;
Reduced IGF 1 levels are associated with sarcopenia, frailty and disease severity in alcohol associated cirrhosis patients with DC or AH. Modulation of GH IGF 1 axis is a potentially disease modifying target in cirrhosis.

|||||||||| Improvement of liver frailty, hand grip strength and mid-upper arm circumference in cirrhotic patients after TIPS insertion (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1897;
Furthermore, our results suggest that individuals with a high degree of frailty benefit most. This should be considered for patient selection.

|||||||||| Insulin resistance and sarcopenia as comorbid conditions in patients with MASLD (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1649;
This should be considered for patient selection. The mechanisms of pathogenesis of sarcopenia and MASLD are common: insulin resistance, increased inflammation, secretion of myokines by skeletal muscles, myostatin, and decrease in adiponectin level.

|||||||||| Obese patients with sarcopenic obesity have a more severe metabolic phenotype and hepatic disease and exhibit less metabolic improvement after bariatric surgery (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1646;
The mechanisms of pathogenesis of sarcopenia and MASLD are common: insulin resistance, increased inflammation, secretion of myokines by skeletal muscles, myostatin, and decrease in adiponectin level. The SO diagnostic index identifies a population of pts with more severe metabolic and hepatic disease, with lower weight loss post-BaS and with lesser metabolic benefit from BaS.

|||||||||| Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1642;
Despite lower BMI, sarcopenic patients exhibit a similar extent of hepatic steatosis and CVD compared to those without sarcopenia. For those with additional metabolic risk factors like diabetes and hypertension, the risk of CVD is aggravated by sarcopenia.

|||||||||| The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1617;
In non-cirrhotic MASLD patients, the presence of sarcopenia at baseline reduces over time, despite lifestyle intervention, the chance of improvement in liver damage and promotes worsening of cardiovascular damage. These findings should prompt us to screen all patients at diagnosis of MASLD for the presence of sarcopenia.

|||||||||| Lower aspartataminotranspherase activity is associated with dynapenia in middle-aged patients with metabolic dysfunction-associated steatotic liver disease (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1582;
Our data demonstrate that AST activity which is often used as a marker of liver fibrosis progression (mainly as a component of non-invasive indices), is also associated with the presence of dynapenia in MASLD. Dynapenia is an early symptom of sarcopenia, which may negatively influence the ability of patients to perform physical activity, an established effective treatment strategy in MASLD, and affect disease outcome.

|||||||||| Construction and validation of a nomogram prediction model for predicting cirrhosis-related deaths based on severe sarcopenia and clinical serological indicators (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1479;
Dynapenia is an early symptom of sarcopenia, which may negatively influence the ability of patients to perform physical activity, an established effective treatment strategy in MASLD, and affect disease outcome. Severe sarcopenia increases the risk of death in cirrhotic patients by more than 3-fold and significantly affect the survival prognosis of patients.The nomogram prediction model based on BMI,MELD score,and severe sarcopenia has great clinical predictive value for liver disease-related deaths in cirrhotic patients.

|||||||||| Anthropometric muscle mass indicators are effective in diagnosing muscle mass loss but are unable to diagnose myosteatosis, thus failing to identify all patients with sarcopenia in liver cirrhosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1476;
Among anthropometric indices, MAC is as effective as the skeletal mass index in identifying sarcopenia in LC. However, no anthropometric marker assessing muscle mass can diagnose myosteatosis, and therefore about one third of sarcopenic cases could be misdiagnosed as non-sarcopenic, if myosteatosis is not determined by imaging studies.

|||||||||| Independent association of loss of skeletal muscle mass with long-term liver-related mortality in cirrhotic patients (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1474;
The utilization of LSMM can be valuable in the prediction of liver-related mortality among individuals diagnosed with liver cirrhosis. Paying attention to the management of skeletal muscle might play a role in enhancing the prognosis of patients with cirrhosis.

|||||||||| The relationship between abnormal body composition by computed tomography imaging and long-term mortality in patients with cirrhosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1473;
Commented [?2]: ??????CT??? Commented [?3]: ???????

|||||||||| Prevalence of dysgeusia in patients with advanced chronic liver disease, relationship with the liver-disease progression status, and impact on malnutrition-sarcopenia-frailty (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1467;
Commented [?3]: ??????? The prevalence of dysgeusia, increasing in parallel to the worsening of liver disease, promoted sarcopenia-frailty pictures, negatively influencing ACLD patients' outcomes.

|||||||||| Validation of an easy-to-use malnutrition screening in cirrhosis to predict outcome (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1461;
Neither other malnutrition scores such as RFH, NRS and MNA, nor markers of sarcopenia were predictive in the multivariate prediction model for mortality in this patient cohort. GMS can be implemented easily into an electronic patient record system and therefore can provide an added value for cirrhotic patient care to identify patients with malnutrition and high risk of death, who may benefit from intensive nutritional therapy.

|||||||||| Unveiling the role of GH-IGF1 axis in decompensated cirrhosis: implications for sarcopenia, frailty, decompensations, and mortality (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1456;
Low IGF1 contributes to complications and mortality in cirrhosis outpatients. Our findings suggest that modulating this axis could be a novel approach for improving patient outcomes in decompensated cirrhosis.

|||||||||| Screening and assessing Sarcopenia in liver cirrhosis: feasibility and implications for clinical outcomes (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1455;
The current EWGSOP2 algorithm for diagnosing sarcopenia has limited applicability in patients, as screening by SARC-F identifies only a minority of patients with high risk for sarcopenia characterized by reduced muscle strength and/or low phase angle by BIA - both associated with malnutrition and adverse outcome in this patient group. A valid screening instrument for sarcopenia in patients with liver cirrhosis is needed and should be addressed in further studies

|||||||||| Feasibility of bedside ultrasonography of rectus femoris muscle for sarcopenia diagnosis in liver cirrhosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1452;
Both, low RFM thickness and cross-sectional area are associated with lower muscle strength. These findings underscore the potential of ultrasonography as a practical bedside tool for diagnosing sarcopenia in patients with cirrhosis.

|||||||||| Upper extremity skeletal muscle index to assess sarcopenia in patients with cirrhosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1450;
Normative values for the upper extremity SMI for patients with decompensated liver cirrhosis and sarcopenia have been developed. It makes it possible to correctly evaluate the index in dynamics against the background of patients' treatment.

|||||||||| Rectus femoris cross sectional area predicts 90-day readmission in patients hospitalized for an acute decompensation of cirrhosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1427;
Low muscle mass assessed by RF-CSA independently predicts 90 day-readmission in patients with cirrhosis surviving a hospitalization for AD. These findings suggest that preventing muscle loss and/or promoting increases in muscle mass could be potential targets for strategies aimed at preventing readmissions.

|||||||||| Effect of adipose-related parameters on survival in patients with cirrhosis: a systematic review and meta-analysis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1421;
These findings suggest that preventing muscle loss and/or promoting increases in muscle mass could be potential targets for strategies aimed at preventing readmissions. Different adipose parameters exhibited varying prognostic value: decreased SATI or MR, increased VSR, and concurrent myosteatosis or SO were independently associated with a higher risk of mortality in patients with cirrhosis.

|||||||||| Six years long-lasting clinical benefits of previous short-term resistance training in cirrhosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1418;
Also, mortality was lower although not maintaining statistical significance. The mechanisms of this long-lasting positive effect of short-term training are unresolved but are likely related to a reduction in sarcopenia maintained by life- style changes.

|||||||||| Does the use of liver frailty index in liver transplant assessment aid clinical decision making and correlate with patient outcomes? (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1190;
LFI correlates well with other commonly used pre transplant assessments of sarcopenia and anaerobic threshold testing. Our data corroborates published data supporting LFI as an effective tool to predict liver transplant outcomes, including likelihood of being listed for transplant and duration of post transplant inpatient stay.

|||||||||| Development of cardiometabolic dysfunction and sarcopenia in a mouse model of MASH (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1103;

|||||||||| Evaluation of secondary sarcopenia and Fontan circulatory failure in post-Fontan hepatic complications (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_795;
Sarcopenia is considered a predictive factor for Fontan circulatory failure and a risk factor for the progression of liver fibrosis due to FALD. The evaluation of skeletal muscle mass may serve as a comprehensive screening tool for multi-organ failure in cases of Fontan circulation.

|||||||||| Muscle composition as a predictor of advanced fibrosis in chronic liver disease (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_594;
Low MVZ but not high MFI was predictive of advanced fibrosis. However, this relationship did not reach the threshold for significance when adjusting for age.

|||||||||| Simultaneous assessment of skeletal muscle mass and handgrip strength to identify patients with NAFLD at high risk of advanced liver fibrosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_581;
In NAFLD patients, male sex and BMI were independently associated with discordance in diagnosing sarcopenia via ASM by BIA and HGS. Moreover, the combined use of the methods helped identify those at high risk of advanced liver fibrosis.

|||||||||| Nitrogen recycling by the gut microbiome in sarcopenia (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_516;
This gives first indications for the potential role of the gut microbiome and its nitrogen recycling potential in sarcopenia. More pronounced differences in women and patients with cirrhosis, two groups who are disproportionally affected by sarcopenia, point towards a potential precision medicine target.

|||||||||| Investigating gut microbial biomarkers for early detection of sarcopenia in individuals at various stages of alcohol-related liver disease (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_502;
These findings suggest that early-stage ALD patients with sarcopenia, displaying a depleted Bacteroides species profile, may benefit from modifying gut microbiota. This could enhance clinical outcomes and improve the quality of life in ALD with sarcopenia individuals.

|||||||||| Exercise alters immune cell senescence and inflammation in cirrhosis patients with sarcopenia (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_462;
Our results clearly document the positive immunological and molecular alterations associated with exercise in sarcopenic cirrhosis patients. Single supervised exercise program, improve immune senescence, and reduce inflammation and can be of great help in patients with advanced cirrhosis and high MELD.

|||||||||| Retrospective data, Review, Journal: Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis. (Pubmed Central) - Apr 1, 2024
LSMM is associated with worse survival outcomes among adults with haematologic malignancies. Further research into understanding the underlying mechanism of this association and mitigating the negative effects of LSMM among adults with haematologic malignancies is needed.

|||||||||| Review, Journal: Perioperative Considerations in Older Kidney and Liver Transplant Recipients: A Review. (Pubmed Central) - Apr 1, 2024
Postoperative concerns include controlling acute postoperative pain; preventing cardiovascular complications and delirium; optimizing immunosuppression; preventing perioperative kidney injury; and avoiding nephrotoxicity and rehabilitation. Future studies are needed throughout the perioperative period to identify interventions that will improve patients' preoperative physiologic status, prevent postoperative medical complications, and improve medical and patient-centered outcomes in this vulnerable patient population.

|||||||||| Journal, Metabolomic study: Metabolomic response to acute resistance exercise in healthy older adults by 1H-NMR. (Pubmed Central) - Apr 1, 2024
P3
Future studies are needed throughout the perioperative period to identify interventions that will improve patients' preoperative physiologic status, prevent postoperative medical complications, and improve medical and patient-centered outcomes in this vulnerable patient population. This study demonstrates that while many exercise-responsive metabolites change similarly in young and older adults, several demonstrate age-dependent changes even in the absence of evidence of sarcopenia or frailty.

|||||||||| Journal: Social-media based Health Education plus Exercise Programme (SHEEP) to improve muscle function among community-dwelling young-old adults with possible sarcopenia in China: A study protocol for intervention development. (Pubmed Central) - Apr 1, 2024
After this, there will be a three-week pre-test phase, followed by a semi-structured interview to further modify the theory-based conceptual model and the social-media based intervention strategy. The focus of the data analysis will be on thematic analysis of qualitative data primarily derived from the group interview and the semi-structured interview with key stakeholders.

|||||||||| Journal: Response Letter to Correspondence: Methodological considerations in evaluating sarcopenia and frailty in elderly gastrointestinal cancer patients. (Pubmed Central) - Apr 1, 2024
The focus of the data analysis will be on thematic analysis of qualitative data primarily derived from the group interview and the semi-structured interview with key stakeholders. No abstract available

|||||||||| Journal: Risk of sarcopenia and mobility of older adults during the COVID-19 pandemic: the longitudinal data from the REMOBILIZE study. (Pubmed Central) - Apr 1, 2024
Mobility trajectories reported in older people at risk of sarcopenia were negatively influenced by insufficient level of physical inactivity and pre-existing moderate to severe functional limitation. Health and social interventions should be target to avoid mobility limitation during and after the COVID-19 pandemic.

|||||||||| Journal: Effect of a 12-Week Multi-Exercise Community Program on Muscle Strength and Lipid Profile in Elderly Women. (Pubmed Central) - Apr 1, 2024
Regular physical activity is very important for improving the health and QoL of elderly women, and as a result of applying a customized program, effects such as increased muscle index, improvement of sarcopenia, and improvement of blood lipid status were confirmed. Therefore, it is believed that the physical activity program developed through this study can be applied as a community program for elderly women.

|||||||||| Biomarker, Journal: Myostatin and Activin A as Biomarkers of Sarcopenia in Inflammatory Bowel Disease Patients. (Pubmed Central) - Apr 1, 2024
Positive correlations were found between MSTN levels and Muscle Mass Index (rho = 0.31; p < 0.005) and hand grip strength (rho = 0.34, p < 0.05) in the IBD patients. The determination of serum levels of MSTN and Act A may be useful in the early diagnosis of sarcopenia in IBD patients.

|||||||||| Preclinical, Journal: Effect of HY7602 Fermented Deer Antler on Physical Fatigue and Antioxidant Activity in Mice. (Pubmed Central) - Apr 1, 2024
Notably, FA treatment significantly upregulated the activities of the antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione/oxidized glutathione ratio (GSH/GSSG) and increased the mRNA expression of antioxidant genes (SOD1, SOD2, CAT, GPx1, GPx2, and GSR) in the liver. Conclusively, FA is a potentially useful functional food ingredient for improving fatigue through its antioxidant effects.

|||||||||| Retrospective data, Journal: Phase Angle as a Marker of Physical Function in Non-Sarcopenic Rheumatoid Arthritis. (Pubmed Central) - Apr 1, 2024
Bioelectrical impedance analysis-derived PhA is a valuable guidance tool for RA management. PhA can be a useful clinical biomarker of muscle status in non-sarcopenic RA patients.

|||||||||| Journal: Mapping the causal associations of cytokines with sarcopenia and aging traits: Evidence from bidirectional Mendelian randomization. (Pubmed Central) - Apr 1, 2024
PhA can be a useful clinical biomarker of muscle status in non-sarcopenic RA patients. Twenty-seven factors were causally related to sarcopenia and aging traits, and the causal effects of IL16, CTACK, MIP1b and PDGFbb were proven in both analyses with two significance thresholds.

|||||||||| Journal: Relationship between adiponectin and muscle mass in patients with metabolic syndrome and obesity. (Pubmed Central) - Apr 1, 2024
Twenty-seven factors were causally related to sarcopenia and aging traits, and the causal effects of IL16, CTACK, MIP1b and PDGFbb were proven in both analyses with two significance thresholds. Serum adiponectin levels are negatively associated with low skeletal muscle mass among obese subjects with metabolic syndrome who are older than 60

|||||||||| Journal: Impact of sarcopenia on the short-term and long-term outcomes of intrahepatic cholangiocarcinoma undergoing hepatectomy: A multi-center study. (Pubmed Central) - Apr 1, 2024
Serum adiponectin levels are negatively associated with low skeletal muscle mass among obese subjects with metabolic syndrome who are older than 60 Sarcopenia is negatively associated with both postoperative complications and survival prognosis of iCCA undergoing hepatectomy.

|||||||||| Journal: PPI use is not associated with bone microarchitecture and strength assessed with HR-pQCT after three-years follow-up in patients visiting the Fracture Liaison Service. (Pubmed Central) - Apr 1, 2024
Compared to non-use, PPI use was not associated with the change of bone microarchitecture and strength in FLS patients at three years of follow-up. These results do not support that an altered bone microarchitecture or strength may contribute to the increased fracture risk associated with PPI use, as reported in observational studies.

|||||||||| Journal: Excessive linoleic acid induces muscle oxidative stress through 5-lipoxygenase-dependent peroxidation. (Pubmed Central) - Apr 1, 2024
Mechanistically, the activation of the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway facilitated the translocation of 5-LOX from the nucleus to the cytoplasm, where 5-LOX oxidized LA, leading to oxidative stress through the generation of aldehydes. This study suggests that 5-LOX is a potential target to prevent the production of harmful aldehydes.

|||||||||| Journal: Sarcopenia augments the risk of excess weight on COVID-19 hospitalization: A prospective study using the Lifelines COVID-19 cohort. (Pubmed Central) - Apr 1, 2024
In this middle-aged population, sarcopenic overweight or obesity elevated the risk of hospitalization for COVID-19 in those infected with COVID-19 more than overweight or obesity alone. These data support the relevance of sarcopenic overweight or obesity as a risk factor beyond the geriatric setting and should be considered in risk stratification in future public health and vaccination campaigns.

|||||||||| Journal: Dual-energy CT applications in musculoskeletal disorders. (Pubmed Central) - Apr 1, 2024
Newer DECT applications to evaluate fat fraction for sarcopenia, Rho/Z application for soft tissue calcification differentiation, 3D rendering, and AI integration are being assessed for future use. In this article we will discuss the established and developing applications of DECT in the setting of MSK radiology as well as the basic principles of dual-energy CT which facilitate them.

|||||||||| Journal: Sarcopenia. (Pubmed Central) - Mar 31, 2024
In this article we will discuss the established and developing applications of DECT in the setting of MSK radiology as well as the basic principles of dual-energy CT which facilitate them. Ambas pruebas presentaron un alto valor predictivo negativo (>70%) para el diagn

|||||||||| Journal: Exploring the Potential of Crassostrea nippona Hydrolysates as Dietary Supplements for Mitigating Dexamethasone-Induced Muscle Atrophy in C2C12 Cells. (Pubmed Central) - Mar 31, 2024
Western blot and gene expression analysis via RT-qPCR demonstrated that AOH downregulated MuRF-1, Atrogin, Smad 2/3, and Foxo-3a, while upregulating myogenin, MyoD, myosin heavy chain expression, and mTOR, key components of the ubiquitin-proteasome and mTOR signaling pathways. Finally, this study suggests that AOH holds promise for alleviating dexamethasone-induced muscle atrophy in C2C12 cells in vitro, offering insights for developing functional foods targeting conditions akin to sarcopenia.

|||||||||| Journal: Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease. (Pubmed Central) - Mar 30, 2024
Specifically, patients with NAFLD and 25-hydroxyvitamin D < 12.7 ng/mL had a significantly higher incidence of muscle mass loss than those with ? 12.7 ng/mL (p = 1.23



	Diseases Companies Products Productz Mechanisms of Action Sites